143 results about "Glucuronate" patented technology

The present invention belongs to the field of biotechnology, and specifically relates to a GmSGT2 gene related to plant height and branch development, and a mutant thereof and the use thereof. A Glycine max mutant having fewer branches and decreased plant height is obtained by means of EMS mutagenesis, and a target gene thereof that is located by means of a map-based cloning technique is a GmSGT2 gene of Hedou 12. It is found through searching that the gene encodes soyasapogenol B glucuronide galactosyltransferase, and can galactosylate soyasapogenol B monoglucuronide, thereby affecting the plant height of Glycine max and reducing the branches of Glycine max. Therefore, the GmSGT2 mutant can be used for cultivating dwarf high-yield Glycine max varieties, and is of great significance in the breeding of ideal plant types of Glycine max and research on important agronomic traits of plants. The mutant has broad application prospects and great research value with regard to understanding the plant height and branch regulation mechanism of Glycine max and improving the process of Glycine max breeding; and can provide an excellent germplasm resource stock for regulating the close planting and high-yield breeding of Glycine max.

The invention belongs to the technical field of biology, and discloses a gene of beta-glucuronidase, an amino acid sequence, an expression vector and a host cell of the beta-glucuronidase and application of the beta-glucuronidase in preparation of glycyrrhetinic acid monoglucuronide. The gene of the beta-glucuronidase is connected with an expression vector and is transformed into a saccharomyces cerevisiae cell, so that the saccharomyces cerevisiae engineering strain with high yield of the beta-glucuronidase is successfully constructed. The glycyrrhizic acid can generate a single product glycyrrhetinic acid monoglucuronide under the catalytic action of the enzyme, and no by-product is generated, so that the aim of efficiently, specifically and safely preparing glycyrrhetinic acid monoglucuronide is fulfilled, and the application and development prospect is wide.

The invention provides a method for extracting acacetin-7-O-glucuronide from dracocephalum moldavica, and relates to the technical field of medicine extraction. The method comprises the following steps: heating and extracting dracocephalum moldavica or dracocephalum moldavica products by adopting an alkaline solution, and precipitating the obtained extracting solution under the condition that the pH value is 1-3 to obtain a precipitate extract; mixing n-hexane, ethyl acetate, ethanol and water, and layering to obtain an upper phase solution and a lower phase solution; and dissolving the precipitate extract with a lower-phase solution, carrying out high-speed counter-current chromatography separation on the obtained sample solution, and collecting an acacetin-7-O-glucuronide fraction according to a chromatogram. According to the method, alkali extraction, acid precipitation and high-speed counter-current chromatography are combined, process conditions are optimized, the high-purity monomer of acacetin-7-O-glucuronide in dracocephalum moldavica is rapidly prepared, and the process is simple.

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The invention relates to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating urolithiasis and preparation and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials and monomers in parts by weight: 10 to 30 parts of endothelium corneum gigeriae galli, 10 to 30 parts of rhizoma phragmitis, 10 to 30 parts of poria cocos, 10 to 20 parts of radix angelicae sinensis, 10 to 20 parts of herba cistanche, 10 to 20 parts of herba cepbalanoplosis segeti, 10 to 15 parts of fructus gardeniae, 5 to 10 parts of liquorice root and 1 to 6 parts of gossypotin 8-O-glucuronide. According to the traditional Chinese medicine theory of clearing heat, treating stranguria, dissolving stone and strengthening body resistance, modern pharmacological research is combined, scientific compatibility is carried out through chemical cutting, the synergistic effects of clearing heat, cooling blood, inducing diuresis, treating stranguria, dissolving stone, relieving pain, tonifying kidney and strengthening body resistance are achieved, the preparation process is efficient and controllable, and clinical application is safe and effective.

The present invention discloses a method for constructing a fingerprint of Gualou Niu Bang decoction, relating to the technical field of analytical chemistry. The method is simple and has high precision, stability, and repeatability. Determination revealed that seven components, including geniposide, liquiritin, hesperidin, arctiin, baicalin, melaleucalyptol A-7-O-β-D-glucuronide, and wogonin, can be used as common characteristic peaks in the fingerprint of Gualou Niu Bang decoction for identification research.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention discloses a lutein composition for relieving asthenopia and a preparation method of the lutein composition, and belongs to the field of functional foods. Phycocyanin and kelp polyphenol are mixed and react to obtain modified phycocyanin; fucoidin and beta-glucuronidase are mixed and react to obtain modified fucose; mixing the fish collagen peptide and zinc chloride to react to obtain a collagen peptide-zinc chelate; the xanthophyll siliceous cage compound and the modified phycocyanin are mixed and react to obtain a first compound; mixing and reacting the first compound and modified fucose to obtain a second compound; mixing and reacting the second compound, collagen peptide-zinc chelate and krill oil to obtain a lutein compound; mixing and reacting the second compound, collagen peptide-zinc chelate and krill oil, adding trehalose, and mixing and reacting to obtain a xanthophyll compound; and mixing the xanthophyll compound and maltodextrin to obtain the xanthophyll composition.

The invention discloses a beta-glucuronidase mutant and application thereof, and belongs to the technical field of genetic engineering and protein engineering modification. The beta-glucuronidase mutant disclosed by the invention has the following mutation on the basis of an amino acid sequence as shown in SEQ ID NO.3: T512S or T512A. The catalytic efficiency of the beta-glucuronidase mutant T512S is improved by 13.92 times compared with that of AtGUS (-3t), and the beta-glucuronidase mutant T512S shows remarkable industrial application potential.

The present invention discloses a preparation method of glucurone, which relates to the technical field of esterification reactions. The method comprises the following steps: adding inositol oxidase to an inositol feed solution for conversion to obtain a conversion solution, and successively subjecting the conversion solution to filtration, ion exchange, decolorization, thermal concentration, and lactonization crystallization steps to obtain crude glucurone. The preparation method of the present invention uses inositol as a raw material, and after converting inositol into glucuronic acid solution under the action of an enzyme, adopts filtration, ion exchange, decolorization, thermal concentration, and lactonization crystallization steps to prepare crude glucurone. By adopting the technical solution of the present invention to prepare glucurone, the problems of low extraction rate of crude products, severe operating pressure, strict equipment requirements, and environmental pollution existing in the nitric acid oxidation method using starch as a raw material are solved. At the same time, the present invention uses inositol as a raw material, which is a new process different from the process using starch as a raw material, and has the advantages of low production cost, short cycle, and industrialization feasibility.

The present application relates to the technical field of antibody conjugated drugs, in particular to a drug conjugate with sustained-release property, an antibody conjugated drug and application thereof. The drug conjugate Payload is a payload selected from a drug molecule with cytotoxicity; X is a heteroatom in the payload, selected from O or N; R4 and R5 are independently selected from hydrogen, an alkyl group or other chemical modification groups; R1, R2, R3 and R6 are independently selected from hydrogen, an amino group, a group containing an ether bond, a hydrophilic group, a halogen, an alkyl group or other chemical modification groups; and Glu is a glucuronic acid group. The present application has the advantages of achieving sustained-release effect, increasing stability, avoiding possible non-specific rupture of carbamate bonds in in-vivo circulation, improving the half-life of ADC drugs in blood circulation, reducing toxicity and increasing drug efficacy, and achieving more effective and safe treatment effect due to the sustained-release mechanism which maintains local toxin concentration in a more reasonable killing interval and reduces systemic toxic side effects.

The invention relates to the technical field of pharmaceutical analysis, and discloses a method for simultaneously determining the contents of various components in Shuanling antidiarrheal granules based on a UPLC-QQQ-MS / MS. The contents of 18 components in the Shuanling antidiarrheal granules are simultaneously determined by using an ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometer. The 18 components comprise adenosine, gallic acid, protocatechuic acid, neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, liquiritin, ellagic acid, kaempferitrin, narirutin, hesperidin, baicalin, oroxylin A-7-O-beta-D-glucuronide, wogonin, baicalein, wogonin, pachymic acid B and pachymic acid A. The invention further discloses a preparation method of the pharmaceutical composition. Through the UPLC-QTRAP-MS / MS combined technology, the technical prejudice that single component depends on in quality control of the traditional Chinese medicine compound preparation is broken through, the key problems that multiple components in a complex matrix are difficult to separate, low-content components are difficult to detect and the like are solved, efficient, accurate and synchronous determination of 18 components is achieved, and the method is suitable for large-scale popularization and application. A new reference path is opened up for modernized quality control of the traditional Chinese medicine compound preparation.

The invention discloses a preparation method and application of a quercetin derivative grafted with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione with a blood sugar reducing function. According to the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound disclosed by the invention, the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is prepared by linking quercetin-3-O-glucuronide with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione, the structural formula of the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is shown as a formula (I), and the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound prepared by the invention has the function of reducing blood sugar and can be used for preparing medicines for treating diabetes mellitus.

Provided herein are plants, plant parts, a population of plants or plant parts, and plant products (e.g., seed composition, protein composition) comprising reduced activity of a protein-related polypeptide [e.g., stomatal cytokinesis defective 2 (SCD2), SCD2A, SCD2B, response to dehydration 22 (RD22), glucuronidase 3 (GUS3), GUS3A, glycosyl hydrolase family 10 protein B (GH10B), protein phosphatase 2A beta subunit (PP2AB), PPA2BA, PP2ABAB, alpha / beta-hydrolases superfamily protein (ABH), ABHA, ABHB, calmodulin-binding transcription activator protein 2 (CAMTA2), CAMTA2A, CAMTA2B, cinnamyl-alcohol dehydrogenase (CAD1), beta-ketoacyl reductase 1 (KCR1), KCR1A, or KCR1B], and compositions and methods of producing such plants and plant parts. The plants, plant parts, population of plants or plant parts, or plant products can have a genetic mutation that reduces the protein-related polypeptide activity, which can be one located at least partially in a protein-related gene (e.g., CAD1) or its homolog or in its regulatory region, and can have increased protein content and / or white flake protein content.

This invention discloses the application of Ganoderma lucidum strain SS30 in the preparation of drugs for treating cancer, belonging to the field of biotechnology. This invention provides a polysaccharide from the mycelium of Ganoderma lucidum strain SS30, composed of glucose, galactose, mannose, fucose, xylose, arabinose, rhamnose, glucuronic acid, glucosamine, ribose, and lacturonic acid. This polysaccharide exhibits significant inhibitory effects on transplanted pancreatic cancer and primary colorectal cancer, and can achieve its cancer-treating effect by enhancing immune function and reducing the level of oxidative products. It provides new materials for the development and utilization of Ganoderma lucidum and its products, and lays a research foundation for the development of cancer-related drugs and the study of cancer treatment mechanisms.

This invention discloses a recombinant glucuronide C5 epimerase mutant, expression vector, recombinant expression engineered bacteria, and their culture and induction methods, belonging to the field of biotechnology. The recombinant enzyme sequence is formed by fusing a truncated (N29–N617) mutation (V173R–V197K–A239V–N269E) with an N-terminal maltose-binding protein (MBP) tag to a human glucuronide C5 epimerase (C5-epi). The recombinant glucuronide C5 epimerase mutant exhibits higher activity, 2.1 times that of the recombinant wild-type, and greater stability, retaining 72.5% of its activity after 5 days at room temperature. Furthermore, the soluble expression level of this recombinant mutant glucuronide C5 epimerase is increased by 4-fold.

The invention discloses an oxgall-tolerant in-vitro calculus bovis culture transformation strain and application thereof, and belongs to the technical field of calculus bovis culture. The strain is obtained by separating and purifying fresh ox bile, is identified to belong to escherichia coli, has excellent ox bile tolerance, has the characteristics of beta-glucuronidase, high bezoar conversion rate and high safety, and can be used in the production of in-vitro artificial cultivation of bezoar. The strain is a brand new strain for in-vitro calculus bovis transformation, not only enriches a strain resource library of calculus bovis transformation bacteria, but also provides a new thought for deep research of subsequent in-vitro calculus bovis culture.

This invention provides the use of β-glucuronidase in the preparation of an antidote for the prevention and / or treatment of zearalenone poisoning, and an antidote for the prevention and / or treatment of zearalenone poisoning, belonging to the field of feed additives. This invention, for the first time from the perspective of in vivo exposure control in animals, proposes a method to reduce the overall ZEN exposure level by inhibiting the activity of intestinal bacterial β-glucuronidase. The technical path is clear and highly operable. This is achieved through in vivo toxicokinetic parameters (AUC, C...). max Changes in (and / or MRT) objectively reflect a reduction in ZEN exposure levels in vivo, and the technical effects are quantifiable and verifiable. The β-glucuronidase inhibitors used in this invention are widely available, particularly suitable for the field of feed additives, and have promising application prospects.

The invention discloses an application of luteolin-7-diglucuronide in preparation of a medicine for resisting liver fibrosis related diseases. According to the invention, two animal models, namely a CCl4-induced hepatic fibrosis mouse model and a high-fat, high-cholesterol and high-fructose (GAN) diet and CCl4-induced NASH mouse, are adopted; the results respectively prove that the luteolin-7-diglucuronide has obvious inhibition of mouse collagen deposition and exerts anti-hepatic fibrosis activity on CCl4 induced hepatic fibrosis mice and GAN diet combined CCl4 induced NASH mouse models. Besides, the luteolin-7-diglucuronide is proved to be capable of remarkably inhibiting pathological phenotypes such as formation of fat vacuoles, inflammatory cell infiltration and the like of NASH mice through a GAN diet and CCl4 induced NASH mouse model, and the luteolin-7-diglucuronide is proved to have an application prospect of being developed into an anti-NASH medicine.

The invention relates to a uridine diphosphate-glucose dehydrogenase mutant and an application of the uridine diphosphate-glucose dehydrogenase mutant in synthesis of uridine diphosphate-glucuronic acid. The amino acid sequence of the uridine diphosphate-glucose dehydrogenase mutant D7P166M / I169A is as shown in SEQ ID NO. 2, and the nucleotide sequence of the coding gene is as shown in SEQ ID NO. 1. The invention also provides an application of the mutant in preparation of uridine diphosphate-glucuronic acid, and a method for preparing uridine diphosphate-glucuronic acid by using the mutant. Experimental determination shows that the melting temperature of the mutant is increased by 30 DEG C compared with that of a wild type, the activity is improved by 20%, and a powerful tool is provided for enzymatic synthesis of uridine diphosphate-glucuronic acid compounds. Compared with a conventional synthesis pathway, the method for synthesizing uridine diphosphate-glucuronic acid through immobilized enzyme flow provided by the invention can be used for stably and efficiently synthesizing for a long time, and is beneficial to reducing the cost and realizing industrial synthesis.

Disclosed is a chemical synthesis method for Pseudomonas aeruginosa O5 serotype O-antigen oligosaccharide, which belongs to the field of chemical synthesis. In the disclosure, O-antigen trisaccharide is constructed with a D-glucuronic acid building block and a D-fucosamine building block, where the stereoselective synthesis of a 1,2-α-cis-glycosidic bond of D-fucosamine depends on remote acyl participation and reagent regulation, and synthesis of two types of 1,2-β-trans-glycosidic bonds of 2,3-diaminomannuronic acids is achieved via SN2 nucleophilic substitution of azido at position C2; and via selective assembly of protecting groups, orthogonal modification of modifying groups, and regulation of the reactivity of glycosyl donors and acceptors, multifunctional modified O-antigen target trisaccharide is successfully prepared. According to the method in the disclosure, the raw materials are cheap and easily available, and the preparation method is simple and easy to repeat. Therefore, the method has a very good application prospect in developing vaccines against P. aeruginosa.

A glucuronidase activator including an active ingredient that is a Levilactobacillus brevis strain I-3141 deposited under accession number CECT 7480.

This invention provides an in vitro cultured bezoar, its preparation method, and its application, belonging to the field of traditional Chinese medicine preparation technology. The preparation method of this invention involves obtaining a bile-resistant, high-β-glucuronidase-active *Escherichia coli* strain through bile gradient acclimation, which is then combined with *Enterococcus faecalis* to form a functional bacterial community. This community is then cultured in vitro through a three-stage process of proliferation, transformation, and crystallization, followed by gradient calcium ion-induced crystallization and vacuum freeze-drying to obtain in vitro cultured bezoar. This invention aims to solve the problems of low conversion efficiency, uneven crystallization, insufficient content of effective components, and unstable product quality in existing technologies. The obtained in vitro cultured bezoar product has significantly higher bilirubin and conjugated bile acid contents than the standards of the *Chinese Pharmacopoeia*, and the process is stable, controllable, and suitable for industrialization.

The invention discloses a stringy stonecrop herb polysaccharide extraction process which comprises the following steps: drying and crushing stringy stonecrop herb, adding water according to a material-liquid ratio of (1: 20)-(1: 60), extracting, concentrating, and carrying out alcohol precipitation to obtain crude polysaccharide; deproteinizing, dialyzing and freeze-drying; carrying out gradient elution and purification to obtain sedum sarmentosum polysaccharide SSBP; an extraction process is optimized through a response surface method, optimal conditions are selected, and the yield of crude polysaccharide reaches 19.06%; according to structural characterization, SSBP is acidic polysaccharide, the molecular weight is 7.484 kDa, 36.12% of uronic acid is contained, monosaccharide is composed of rhamnose, arabinose, galactose, galacturonic acid and glucuronic acid, and the molar ratio of rhamnose to arabinose to galactose to galacturonic acid to glucuronic acid is 12.85: 19.13: 18.98: 35.73: 3.35; an in-vitro activity experiment shows that the SSBP has good antioxidant activity and remarkable anti-inflammatory activity, the release of RAW264.7 macrophage NO induced by LPS and the secretion of IL-6, IL-1beta and TNF-alpha can be inhibited in a dose-dependent manner, and the inhibition rates under the concentration of 1.2 mg / mL respectively reach 74.41%, 92.53%, 95.27% and 95.73%; and a new scheme is provided for deep development of sedum sarmentosum polysaccharide and preparation of anti-inflammatory and anti-oxidation products.

The invention discloses application of C-phycocyanin and D-glucuronic acid in directly improving sperm motility in vitro and improving sperm motility after freezing recovery, and belongs to the technical field of biological medicine. According to the present invention, the mixed solution of D-glucuronic acid, C-phycocyanin, and D-phycocyanin has significant effects of in-vitro sperm motility promotion and sperm function protection, can be used for preparing the sperm motility improving drug or the sperm treatment reagent in the assisted reproduction technology, and has good application prospects.

The invention discloses an enzyme for metabolizing glyphosate as well as a gene promoter and application thereof. According to the invention, the glyphosate tolerant germplasm Kitaake is screened for the first time. Moreover, the glycosyl transferase gene GRGT1 (Os04g0206500) which plays a key role in improving the glyphosate tolerance is identified in Kitaake for the first time, and the gene expression level under the stress of glyphosate is remarkably improved due to deletion of a single base A at a site 803 in a promoter region of the glycosyl transferase gene GRGT1 (Os04g0206500). The GRGT1 protease can catalyze a glycosylation reaction between glyphosate and two glycosyl donors UDP-glucose and UDP-glucuronic acid to generate low-toxicity derivatives M331 and M345, so that the residue of glyphosate in rice is reduced. The invention systematically discloses a glyphosate-resistant glycosylation metabolism mechanism of rice, discovers a new glyphosate metabolism gene, and provides a basis for creating efficient resistant germplasm resources.

The application discloses a kind of in-vivo cultivation of bovine calculus bezoar gel and preparation method thereof, it is related to in-vivo cultivation of bovine calculus bezoar technical field.A kind of in-vivo cultivation of bovine calculus bezoar gel, including following mass component: with mass percentage, 0.1%~5% drug depot, 8%~20% high molecular gel skeleton, 0.1%~2% crosslinking agent, 0.1%~2% crosslinking regulator, 50%~65% solvent, 10%~40% crosslinking agent solution;Drug depot exists in the form of β-glucuronidase sustained-release microsphere.The sponge-like porous gel prepared by the application can be injected into the gallbladder of a cow to form a sponge-like bovine calculus bezoar bed through crosslinking reaction, the bovine calculus bezoar bed can slowly release β-glucuronidase, promote the decomposition of conjugated bilirubin into free bilirubin, and finally the free bilirubin forms calcium bilirubinate, which, after combining with mucin, forms bovine calculus bezoar particles, and the particles are enriched by the bovine calculus bezoar bed to form bovine calculus bezoar with high yield and good quality.

The application discloses a kind of feed additive and its application, it is related to feed additive technical field.The prepared feed additive of the application is by mixing sodium glucuronate, glucomannan, dimethyl cyclodextrin, diatomite and sodium lauryl sulfate, then mixed solution is reacted with calcium chloride crosslinking solution, finally form microspheres type feed additive.Compared with prior art, the prepared feed additive of the application is beneficial to the adsorption of deoxynivalenol and zearalenone, amino acid liquid, lemon yellow and titanium dioxide are mixed, then composite bacteria liquid is added to ferment, by feed additive processing, low-temperature drying can retain the nutrient components and biological activity in raw materials, and the biological fermentation protein raw material with good sensory color is obtained.

A method for extracting flavonoid components in Dracocephalum moldavica L., comprising the following steps: mixing Dracocephalum moldavica L. and an alkaline solution for heating extraction; under the condition that the pH value is 1-3, mixing an obtained extract solution with acid for precipitation; dissolving an obtained precipitated extract and then carrying out preparative liquid chromatography separation; and respectively concentrating obtained Fr1-Fr6 fractions until the fractions are dry, so as to sequentially obtain luteolin-7-O-β-D-glucuronide, apigenin-7-O-β-D-glucuronide, diosmetin-7-O-β-D-glucuronide, tilianin, acacetin-7-O-glucuronide, and acacetin.

The invention discloses an application of apigenin-7-O-beta-D-glucuronide in preparation of a medicine for treating fundus diseases, and establishes a model of ischemic fundus diseases of guinea pigs and a model of eyeball conjunctival microcirculation disturbance of rabbits. The prevention and treatment effects of the apigenin-7-O-beta-D-glucuronide on fundus diseases and fundus lesions are researched, and an experimental basis is provided for clinical treatment of the fundus diseases by the apigenin-7-O-beta-D-glucuronide.